Epigenetic Regulation in Lung Cancer

Overview

Journal MedComm (2020)

Specialty Health Services

Date 2023 Oct 30

PMID 37901797

Authors

Shahin Ramazi

Meadeh Daddzadi

Maedeh Dadzadi

Zahra Sahafnejad

Abdollah Allahverdi

Affiliations

Soon will be listed here.

Abstract

Lung cancer is indeed a major cause of cancer-related deaths worldwide. The development of tumors involves a complex interplay of genetic, epigenetic, and environmental factors. Epigenetic mechanisms, including DNA methylation (DNAm), histone modifications, and microRNA expression, play a crucial role in this process. Changes in DNAm patterns can lead to the silencing of important genes involved in cellular functions, contributing to the development and progression of lung cancer. MicroRNAs and exosomes have also emerged as reliable biomarkers for lung cancer. They can provide valuable information about early diagnosis and treatment assessment. In particular, abnormal hypermethylation of gene promoters and its effects on tumorigenesis, as well as its roles in the Wnt signaling pathway, have been extensively studied. Epigenetic drugs have shown promise in the treatment of lung cancer. These drugs target the aberrant epigenetic modifications that are involved in the development and progression of the disease. Several factors have been identified as drug targets in non-small cell lung cancer. Recently, combination therapy has been discussed as a successful strategy for overcoming drug resistance. Overall, understanding the role of epigenetic mechanisms and their targeting through drugs is an important area of research in lung cancer treatment.

Citing Articles

Methylation Biomarkers of Lung Cancer Risk: A Systematic Review and Meta-Analysis.

Dolcini J, Chiavarini M, Firmani G, Brennan K, Cardenas A, Baccarelli A Cancers (Basel). 2025; 17(4).

PMID: 40002283 PMC: 11853407. DOI: 10.3390/cancers17040690.

Epigenetic modifications in early stage lung cancer: pathogenesis, biomarkers, and early diagnosis.

Bi L, Wang X, Li J, Li W, Wang Z MedComm (2020). 2025; 6(3):e70080.

PMID: 39991629 PMC: 11843169. DOI: 10.1002/mco2.70080.

Epigenomic Echoes-Decoding Genomic and Epigenetic Instability to Distinguish Lung Cancer Types and Predict Relapse.

Baumann A, Buribayev Z, Wolkenhauer O, Salybekov A, Wolfien M Epigenomes. 2025; 9(1).

PMID: 39982247 PMC: 11843950. DOI: 10.3390/epigenomes9010005.

Biomarkers for immunotherapy resistance in non-small cell lung cancer.

Rother C, John T, Wong A Front Oncol. 2025; 14:1489977.

PMID: 39749035 PMC: 11693593. DOI: 10.3389/fonc.2024.1489977.

Targeting piRNA-137463 Inhibits Tumor Progression and Boosts Sensitivity to Immune Checkpoint Blockade via De Novo Cholesterol Biosynthesis in Lung Adenocarcinoma.

Zhan Y, Tian F, Fan W, Li X, Wang X, Zhang H Adv Sci (Weinh). 2024; 12(6):e2414100.

PMID: 39692168 PMC: 11809383. DOI: 10.1002/advs.202414100.

References

Esteller M, Corn P, Baylin S, Herman J . A gene hypermethylation profile of human cancer. Cancer Res. 2001; 61(8):3225-9. View

Dearden S, Stevens J, Wu Y, Blowers D . Mutation incidence and coincidence in non small-cell lung cancer: meta-analyses by ethnicity and histology (mutMap). Ann Oncol. 2013; 24(9):2371-6. PMC: 3755331. DOI: 10.1093/annonc/mdt205. View

Gross U, Brzuszkiewicz E, Gunka K, Starke J, Riedel T, Bunk B . Comparative genome and phenotypic analysis of three Clostridioides difficile strains isolated from a single patient provide insight into multiple infection of C. difficile. BMC Genomics. 2018; 19(1):1. PMC: 5749029. DOI: 10.1186/s12864-017-4368-0. View

Pajares M, Alemany-Cosme E, Goni S, Bandres E, Palanca-Ballester C, Sandoval J . Epigenetic Regulation of microRNAs in Cancer: Shortening the Distance from Bench to Bedside. Int J Mol Sci. 2021; 22(14). PMC: 8306710. DOI: 10.3390/ijms22147350. View

Suzuki M, Wada H, Yoshino M, Tian L, Shigematsu H, Suzuki H . Molecular characterization of chronic obstructive pulmonary disease-related non-small cell lung cancer through aberrant methylation and alterations of EGFR signaling. Ann Surg Oncol. 2009; 17(3):878-88. DOI: 10.1245/s10434-009-0739-3. View

Kaufmann W . The human intra-S checkpoint response to UVC-induced DNA damage. Carcinogenesis. 2009; 31(5):751-65. PMC: 2899860. DOI: 10.1093/carcin/bgp230. View

Heller G, Zielinski C, Zochbauer-Muller S . Lung cancer: from single-gene methylation to methylome profiling. Cancer Metastasis Rev. 2010; 29(1):95-107. DOI: 10.1007/s10555-010-9203-x. View

Liu Y, Gao W, Siegfried J, Weissfeld J, Luketich J, Keohavong P . Promoter methylation of RASSF1A and DAPK and mutations of K-ras, p53, and EGFR in lung tumors from smokers and never-smokers. BMC Cancer. 2007; 7:74. PMC: 1877812. DOI: 10.1186/1471-2407-7-74. View

Arrowsmith C, Bountra C, Fish P, Lee K, Schapira M . Epigenetic protein families: a new frontier for drug discovery. Nat Rev Drug Discov. 2012; 11(5):384-400. DOI: 10.1038/nrd3674. View

Liu Y, Lan Q, Siegfried J, Luketich J, Keohavong P . Aberrant promoter methylation of p16 and MGMT genes in lung tumors from smoking and never-smoking lung cancer patients. Neoplasia. 2006; 8(1):46-51. PMC: 1584289. DOI: 10.1593/neo.05586. View

10.

Derynck R, Weinberg R . EMT and Cancer: More Than Meets the Eye. Dev Cell. 2019; 49(3):313-316. PMC: 7672963. DOI: 10.1016/j.devcel.2019.04.026. View

11.

Odogwu L, Mathieu L, Blumenthal G, Larkins E, Goldberg K, Griffin N . FDA Approval Summary: Dabrafenib and Trametinib for the Treatment of Metastatic Non-Small Cell Lung Cancers Harboring Mutations. Oncologist. 2018; 23(6):740-745. PMC: 6067947. DOI: 10.1634/theoncologist.2017-0642. View

12.

Xu M, Xie Y, Ni S, Liu H . The latest therapeutic strategies after resistance to first generation epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs) in patients with non-small cell lung cancer (NSCLC). Ann Transl Med. 2015; 3(7):96. PMC: 4430733. DOI: 10.3978/j.issn.2305-5839.2015.03.60. View

13.

Jin N, George T, Otterson G, Verschraegen C, Wen H, Carbone D . Advances in epigenetic therapeutics with focus on solid tumors. Clin Epigenetics. 2021; 13(1):83. PMC: 8056722. DOI: 10.1186/s13148-021-01069-7. View

14.

Toyooka S, Toyooka K, Maruyama R, Virmani A, Girard L, Miyajima K . DNA methylation profiles of lung tumors. Mol Cancer Ther. 2002; 1(1):61-7. View

15.

Feng H, Zhang Z, Qing X, Wang X, Liang C, Liu D . Promoter methylation of APC and RAR-β genes as prognostic markers in non-small cell lung cancer (NSCLC). Exp Mol Pathol. 2015; 100(1):109-13. DOI: 10.1016/j.yexmp.2015.12.005. View

16.

Gadgeel S . Personalized Therapy of Non-small Cell Lung Cancer (NSCLC). Adv Exp Med Biol. 2015; 890:203-22. DOI: 10.1007/978-3-319-24932-2_11. View

17.

Na Y, Lee S, Kim D, Park J . Promoter methylation of Wnt antagonist DKK1 gene and prognostic value in Korean patients with non-small cell lung cancers. Cancer Biomark. 2013; 12(2):73-9. DOI: 10.3233/CBM-2012-00295. View

18.

Bianchi F, Nicassio F, Marzi M, Belloni E, DallOlio V, Bernard L . A serum circulating miRNA diagnostic test to identify asymptomatic high-risk individuals with early stage lung cancer. EMBO Mol Med. 2011; 3(8):495-503. PMC: 3377091. DOI: 10.1002/emmm.201100154. View

19.

Sharp J, Mailer S, Thomson P, Lefevre C, Nicholas K . Identification and transcript analysis of a novel wallaby (Macropus eugenii) basal-like breast cancer cell line. Mol Cancer. 2008; 7:1. PMC: 2263075. DOI: 10.1186/1476-4598-7-1. View